Pentoxifylline modulates LPS-induced hyperinflammation in monocytes of preterm infants in vitro

Pediatric Research

Volumn 82, Issue 2, 2017, Pages 215-225

  Schüller, Simone S ^a   Wisgrill, Lukas ^a   Herndl, Elisabeth ^a   Spittler, Andreas ^b   Förster Waldl, Elisabeth ^a   Sadeghi, Kambis ^a   Kramer, Boris W ^c,d   Berger, Angelika ^a  

^a UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CD14 ANTIGEN; CD64 ANTIGEN; CD71 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; PENTOXIFYLLINE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; LEUKOCYTE ANTIGEN;

ANTIINFLAMMATORY ACTIVITY; APGAR SCORE; ARTICLE; BLOOD; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GESTATIONAL AGE; HUMAN; IN VITRO STUDY; INFLAMMATION; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PREMATURITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SEPSIS; UMBILICAL CORD BLOOD; ADULT; CHEMICALLY INDUCED; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; NEWBORN;

ADULT; ANTIGENS, CD; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IN VITRO TECHNIQUES; INFANT, NEWBORN; INFANT, PREMATURE; INFLAMMATION; LIPOPOLYSACCHARIDES; MONOCYTES; PENTOXIFYLLINE; PHAGOCYTOSIS;

EID: 85026319732     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2017.41     Document Type: Article

References (32)

1. Stoll BJ, Hansen NI, Higgins RD, et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gramnegative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J 2005; 24: 635-9
2. Chalmers IM, Janossy G, Contreras M, Navarrete C. Intracellular cytokine profile of cord and adult blood lymphocytes. Blood 1998; 92: 11-8
3. Sadeghi K, Berger A, Langgartner M, et al. Immaturity of infection control in preterm and term newborns is associated with impaired toll-like receptor signaling. J Infect Dis 2007; 195: 296-302
4. Schüller SS, Sadeghi K, Wisgrill L, et al. Preterm neonates display altered plasmacytoid dendritic cell function and morphology. J Leukoc Biol 2013; 93: 781-8
5. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007; 7: 379-90
6. Krakauer T, Oppenheim JJ. IL-1 and tumor necrosis factor-alpha each up-regulate both the expression of IFN-gamma receptors and enhance IFN-gamma-induced HLA-DR expression on human monocytes and a human monocytic cell line (THP-1). J Immunol 1993; 150: 1205-1
7. Wisgrill L, Groschopf A, Herndl E, et al. Reduced TNF-α response in preterm neonates is associated with impaired nonclassic monocyte function. J Leukoc Biol 2016; 100: 607-12
8. Förster-Waldl E, Sadeghi K, Tamandl D, et al. Monocyte toll-like receptor 4 expression and LPS-induced cytokine production increase during gestational aging. Pediatr Res 2005; 58: 121-4
9. Lakhani SA, Bogue CW. Toll-like receptor signaling in sepsis. Curr Opin Pediatr 2003; 15: 278-82
10. Shimaoka M, Park EJ. Advances in understanding sepsis. Eur J Anaesthesiol Suppl 2008; 42: 146-53
11. Pammi M, Haque KN. Pentoxifylline for treatment of sepsis and necrotizing enterocolitis in neonates. Cochrane Database Syst Rev 2015; 3: CD004205
12. Shabaan AE, Nasef N, Shouman B, Nour I, Mesbah A, Abdel-Hady H. Pentoxifylline therapy for late-onset sepsis in preterm infants: a randomized controlled trial. Pediatr Infect Dis J 2015; 34: e143-8
13. Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 1993; 187: 447-63
14. D'Hellencourt CL, Diaw L, Cornillet P, Guenounou M. Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline. Int J Immunopharmacol 1996; 18: 739-48
15. Neuner P, Klosner G, Pourmojib M, Knobler R, Schwarz T. Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. Immunology 1997; 90: 435-9
16. Wang W, Tam WF, Hughes CC, Rath S, Sen R. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity 1997; 6: 165-74
17. Szymura-Oleksiak J, Bury J, Lauterbach R, Pawlowski M. Serum Concentrations of pentoxifylline and its metabolites in premature infants with sepsis when administered by continuous intravenous infusion. Pharm Pharmacol Commun 1997; 3: 367-71
18. Lauterbach R, Pawlik D, Kowalczyk D, Ksycínski W, Helwich E, Zembala M. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebocontrolled, double-blind trial. Crit Care Med 1999; 27: 807-14
19. Coimbra R, Melbostad H, Loomis W, Tobar M, Hoyt DB. Phosphodiesterase inhibition decreases nuclear factor-kappaB activation and shifts the cytokine response toward anti-inflammatory activity in acute endotoxemia. J Trauma 2005; 59: 575-82
20. Marcinkiewicz J, Grabowska A, Lauterbach R, Bobek M. Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12 p40 and p35 subunits by murine peritoneal macrophages. Immunopharmacology 2000; 49: 335-43
21. Rieckmann P, Weber F, Günther A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996; 64: 193-200
22. Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol 2009; 9: 447-53
23. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177: 1205-8
24. Howard M, O'Garra A, Ishida H, de Waal Malefyt R, de Vries J. Biological properties of interleukin 10. J Clin Immunol 1992; 12: 239-47
25. Danikas DD, Karakantza M, Theodorou GL, Sakellaropoulos GC, Gogos CA. Prognostic value of phagocytic activity of neutrophils and monocytes in sepsis. Correlation to CD64 and CD14 antigen expression. Clin Exp Immunol 2008; 154: 87-97
26. Falconer AE, Carr R, Edwards SW. Impaired neutrophil phagocytosis in preterm neonates: lack of correlation with expression of immunoglobulin or complement receptors. Biol Neonate 1995; 68: 264-9
27. Lingnau M, Höflich C, Volk H-D, Sabat R, Döcke W-D. Interleukin-10 enhances the CD14-dependent phagocytosis of bacteria and apoptotic cells by human monocytes. Hum Immunol 2007; 68: 730-8
28. Shames BD, Selzman CH, Meldrum DR, et al. Interleukin-10 stabilizes inhibitory kappaB-alpha in human monocytes. Shock 1998; 10: 389-94
29. Ward PA, Lentsch AB. Endogenous regulation of the acute inflammatory response. Mol Cell Biochem 234-235: 225-8
30. Levy O, Coughlin M, Cronstein BN, Roy RM, Desai A, Wessels MR. The adenosine system selectively inhibits TLR-mediated TNF-alpha production in the human newborn. J Immunol 2006; 177: 1956-66
31. Anaya JM, Espinoza LR. Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases. J Rheumatol 1995; 22: 595-9
32. Kreth S, Ledderose C, Luchting B, Weis F, Thiel M. Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock 2010; 34: 10-6